Allogene Therapeutics Q3 2023 Earnings Call Transcript

Quartr
Provided by Quartr
November 2, 2023

There are 12 speakers on the call.

Operator

Hello and thank you for standing by. Welcome to the Allogene Therapeutics Third Quarter 2023 Conference Call. After the speakers' presentation, there will be a question and answer session. You will then hear an automated message advising you that your hand is raised. Please be aware that today's conference is being recorded.

Operator

I would now like to turn the call over to Christine Casciano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Casciano, please go ahead.

Speaker 1

Thank you, operator, and welcome to our call. Today, after market close, Allogene issued press release that provides a business update and financial results for the Q3 of 2023. This press release and today's webcast are both available on our website. Following our prepared remarks, we will host a Q and A session. We ask you to limit your questions to 1 per person as we will keep this call to an hour and do our best to get to as many as possible.

Speaker 1

Joining me today are Doctor. David Chang, President and Chief Executive Officer Doctor. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates and 2023 financial guidance, among other things.

Speaker 1

These forward looking statements are based on current Information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and the latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward looking statements and Allogene disclaims any obligation to update these statements. I'll now turn the call over to David.

Speaker 2

Thank you, Christine, and welcome to all listening to our call today. The last few weeks have been starting in the field of cell therapy. From an uptake in Apollo CAR T sales In the release of abstract this morning for the upcoming American Society of Hematology meeting to witnessing the potential of CAR T therapy beyond oncology, It is clear that we are just at the beginning of what's possible for patients with this modality. While indications outside of oncology have been the focus of the field as of late, something we are keeping a keen eye on, I will focus our call today on CAR T and oncology. Throughout the decades, cancer therapies have come in great waves.

Speaker 2

Cytotoxic Hemotherape was the 1st wave spanning most of the 20th century as fundamental discoveries The second wave was monoclonal antibodies, a scientific breakthrough that even today continues to fuel innovation with follow on technology platforms. I would argue that this way also includes antibody drug conjugates by specific antibody and by specific T cell engagers. The 3rd wave has been a more gradual emergence of targeted therapies in today's omics era. Pathways that govern the behavior of our cells have been delineated, paving away to precisely enter big disease. We are now at the beginning of a 4th great way, the era of engineered cell therapy, The enablement of synthetic biology to harness the power of immune cells is now feasible through the convergence of knowledge of cellular pathways and technological breakthroughs in gene editing and cell engineering.

Speaker 2

But this 4th grade wave can only be fully unlocked when industry makes CAR T accessible to all eligible patients. This was an important topic during recent discussions at both the Future Summit hosted by Steph as well as the American Society For Transplantation and Cellular Therapy sponsored Accelerate Forum on a panel Moderated by Doctor. Peter Marks, Director of Center For Biologic Evaluation and Research and Doctor. Marcelo Peskini at the Center For International Blood and Narrow Transplant Research. At Allogene, we believe That the key to unlocking this potential is allogeneic CAR T.

Speaker 2

And if you will creating the Konami code for cell therapy. For those who know video games, the Konami code was originally a simple sequence of buttons That would give a full set of power ups to make testing easier for developers. The modern day concept of this call is no longer just about making a game easier, Rather, it is now unlocking hidden expert modes, enabling expansion of the game. And that is exactly how we are thinking about our platform. It is creating the economic code for allogeneic cell therapy, For quote, they can be applied not just in the industry's first potentially pivotal trial of an allogeneic CAR T product, but in other harder modes such as earlier line trials, solid tumors, non oncology indications and next generation products.

Speaker 2

And we look forward to the month ahead where certain scientific aspects of this call will come to light, unlocking new opportunities and broadening patient access to the 4th Great Wave. Before I turn the call over to Zach to give a brief overview of what will be presented at I want to officially welcome newest member of our leadership team to his first Allogene quarterly call, Jeff Parker. In this especially challenging market, Jeff's extensive experience in biotechnology across all aspects of finance And business development strategy will be the tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities. I am confident he will be instrumental to our success as we navigate the next chapter. I would now like to turn the call over to Zach.

Speaker 2

Thank you, David. While we focus on execution of our potentially pivotal ALPHA-two global trial with ALLO-five zero one A and relapsed refractory large B cell lymphoma, our 2023 data readouts have been designed to answer foundational questions that support the viability of an allogeneic CAR T product. Over the summer at the American Society of Clinical Oncology Annual Meeting, the European Hematology Association Congress In the International Conference on Malignant Lymphoma and Lugano, we shared the long term durability data from our Phase 1 trials that answered one of the most important questions in the field. Can an off the shelf CD19 CAR T product candidate demonstrate durability comparable to an autologous CAR T therapy in large B cell lymphoma? In CAR T, the best surrogate for duration of response is a 6 month CR rate.

Speaker 2

Based on the data from patients who received Our Phase 2 regimen during the Phase 1 trial, we have now shown that our 6 month CR rate is comparable to what has been reported in the pivotal studies of Kymriah, Yescarta and Briyonzi. In all of these presentations, our safety analysis included all 33 CAR T naive LBCL patients who received Alloy product. Treatment was generally well tolerated with no cases of Grade 3 or higher CRS and no cases of ICANS or GvHD. Cytopenias and infections were manageable and comparable to the experience with autologous CAR T therapies in patients with relapsed refractory LPCL. We showed patients' neutrophil and lymphocyte counts beginning to recover within the 1st month of infusion and achieving baseline levels with kinetics similar to autologous cell therapies.

Speaker 2

Comparability of immune reconstitution in patients receiving investigational ALLO-five 01A to those who receive autologous product Yields important insight into our comparable infection rate. But we wanted to dig deeper and address outstanding questions as it relates to the safety profile of ALLO-six forty seven, our investigational anti CD52 monoclonal antibody When used in conjunction with standard low dose flu PSI, that will be the focus at this year's annual meeting of the American Society of Hematology. At ASH, we will have a comprehensive safety review of all 85 patients treated in the Phase 1 alpha and alpha 2 studies in LBCL and follicular lymphoma To characterize the overall safety profile when ALLO-six forty seven is added to standard lymphodepletion, Because of the risk of rejection by a patient's immune system creating the necessary window of persistence for an allogeneic CAR T likely requires an enhanced approach to lymphodepletion. Different approaches have been used in other allogeneic clinical trials, including high dose chemotherapy that might be associated with severe toxicity. The results of our trials reinforce our belief that in the LBCL patient population, Our unique and proprietary lymphodepletion regimen can set the right conditions for our cell products to induce deep and durable remissions, while keeping the safety in line with approved autologous CAR T therapies.

Speaker 2

Our nuanced understanding of lymphodepletion based on the breadth of our trials fueled our early stage research. This weekend, we look forward to poster presentations at the Society For Immunotherapy of Cancer Annual Meeting highlighting our next generation cloak and dagger technologies designed to help enhance engraftment expansion in the persistence of AlloCAR T cells. In LBCL, while we continue to be pleased with the overall profile demonstrated in our trials, we fully recognize evolving practice patterns with Our CD19 program strategy contemplated this challenge and we are tackling this on two fronts. The first strategy is in the Phase 2 clinical trial execution and we focused on increasing the global footprint of our trials. ALFA-two is now open to enrollment in the U.

Speaker 2

S, Canada, Europe and Australia. Our Phase 2 EXPAND trial designed to demonstrate the superiority of an ALLO-six containing lymphodepletion regimen over a regimen of flucyalone is open to enrollment in the United States and Europe. The second strategy lies in the design of an earlier line trial and how we ultimately think this market will evolve. We are all very excited about our intended approach. When all aspects are locked, we look forward to sharing with you more about this trial and believe it will address many questions you have about our overall approach to treating LBCL.

Speaker 2

Lastly, I'd be remiss if I didn't talk a bit about our Phase 1 TRAVERSE trial with ALLO-three sixteen. We do not take lightly the responsibility we carry to demonstrate the potential of an AlloCAR T in solid tumors. As such, we have taken a very deliberate approach and are proud of the way in which we are conducting this trial. We've continued to gain incredible insights for CAR T and solid tumors that we hope will advance This trial into potentially pivotal phase and even more importantly provide another option for patients with advanced or metastatic renal cell carcinoma. The importance of such data to our investors and the medical community at large cannot be understated.

Speaker 2

So we will now target our next update an academic forum in early 2024. I will now turn the call over to Jeff.

Speaker 3

Thank you, Zach, and good afternoon, everyone. In my 1st few weeks as part of Allogene, I've had the chance to speak now with a handful of our covering analysts and I look forward to getting to know all of our analysts and investors Over the next few months years to come, in these early conversations, the number one question I get is, why did I join Allogene? For me, there is a simple answer. I've been in this industry for over 30 years and I firmly believe that this is one of the best management teams I've ever encountered. As a quick note regarding my background, I worked at Goldman Sachs from 1986 to 2009 in Investment Banking, Ultimately running the West Coast Healthcare Banking practice for the last 10 years of my tenure at the firm.

Speaker 3

Following my time at Goldman Sachs, in 2,009, I decided to move to the company side to serve as the CFO as well as to serve as a Board member with a number of healthcare companies, which I have now done for the last 14 years. Fast forward to this past summer, when I received a call from David, I was immediately intrigued by the opportunity to be a part of this team and to play a role in fulfilling the promise of how allogeneic CAR T products could address the access gap to this important modality. Let me now turn to another of Allogene's strengths, our balance sheet and the careful way in which we manage our resources. We ended the Q3 with $497,700,000 in cash, cash equivalents and investments. As noted on our last quarterly call, based on current assumptions, we expect our cash runway to fund operations into the second half of twenty twenty five.

Speaker 3

In the Q3 of 2023, our research and development expenses were $46,000,000 which includes $6,700,000 of non cash stock based compensation expense. General and administrative expenses were $17,000,000 For the Q3 of 2023, which includes $8,600,000 of non cash stock based compensation expense. Our net loss for the Q3 of 2023 was $61,300,000 or $0.37 per share, including non cash stock based compensation expense of $15,400,000 We continue to expect a decrease in cash, Cash equivalents and investments of approximately $230,000,000 for the full year 2023 and full year 2023 GAAP Operating expenses to be approximately $340,000,000 which includes estimated non cash stock based compensation expense of approximately $80,000,000 This guidance excludes any impact from potential business development activities. With that, we will now open the call for your questions.

Operator

Thank And our first question is going to come from the line of Michael Yee with Jefferies. Your line is open. Please go ahead.

Speaker 4

Great. Thanks. Good afternoon, guys. Thanks for the question. I just wanted to ask On the ongoing progress of the potential pivotal trial, you said you had expanded into different countries.

Speaker 2

Can you just give us a sense

Speaker 4

of, I appreciate it's still early, sort of the blocking and the tackling, Expectation for geographic mix and the progress you're making in terms of the types of patients you think you are getting And whether there's any challenges with other competitors or other types of CAR T, which are things that are weighing on people's minds. And then as a follow-up, you did mention that CD70 is important and I heard that. Can you just clarify why the data would be 2024 not

Operator

Please remain on the line. Your conference will begin shortly.

Speaker 4

Operator, are you still there?

Operator

I am Mr. Yi. Just give them a moment. They're having technical issues and they will be back with us.

Speaker 3

Okay. Thank you.

Operator

You're welcome.

Speaker 2

I remember the question just fine, Michael. Thank you so much and apologies for the technical glitch there. So I don't know how much you heard, Michael, so I'll just start over from the beginning. So regarding the first question around ALFA-two enrollment or Potentially pivotal programs with CE19, we are really excited about the progress we've made on the regulatory front And now we have approval in multiple geographies for both programs and we are enrolling AlphaQ in U. S, Canada, Europe and Australia and expand in U.

Speaker 2

S. And Europe. As far as the patient mix that we anticipate having, we're still bringing in patients from the U. S. And so We don't exactly know how this is all going to shake out in the end, but it will be a nice mix with a significant fraction coming from U.

Speaker 2

S. And then, I think probably a large number coming from ex U. S. As well. And the types of patients that we are getting very much consistent with Patients that we have set out to enroll based on the eligibility criteria.

Speaker 2

And again, we're really focused on Enrolling patients who would have been very similar to those that were enrolled in the autologous pivotal studies from a few years back. For the second question on 3 16, so as far as the timing of the data update, We were sort of always planning towards the end of this year, beginning of next year. And as we mentioned in the prepared remarks that We are just really keen to make sure that we are executing the study well and then also updating With the data and taking that all very, very seriously and not rushing things. So we don't expect that the delay will be Substantial on that data and we just want to make sure that it meets everybody's expectations.

Speaker 5

Operator, we have the next question.

Operator

Our next question is going to come from the line of Salveen Richter with Goldman Sachs. Your line is open. Please go ahead.

Speaker 6

Hey, this is Anna Mida on for Salveen. Thank you for taking our question. Could you first provide an update on The progress of enrollment in the TRAVERSE study, have there been any headwinds there? And then just a second one on the cloaking and DAGGER technology. I guess what other programs are you thinking to incorporate the technology and would multiple myeloma be a possible direction there given the profile to date?

Speaker 6

Thank you.

Speaker 2

Thanks very much. Again, this is Zach. So as far as the traverse enrollment goes, I will say that the enthusiasm that we've been communicating all year since the announcement of the data at AACR earlier in 2023 She has very much persisted and in fact we are continuing to get incoming interest from sites that aren't participating in the trial actively. So I would say that as far as the level of interest goes, it's really quite impressive. And that's Really coming down to that efficacy that we showed back in AACR, reminding everybody that the options for these patients are very And the profile that we showed in April was pretty encouraging to say the least.

Speaker 2

And on the second question around Cloak and Dagger, So the specifics around how which CAR target we choose to Pair with that technology, you're absolutely right. We can do it with either CB19 or BCMA and you're right that the BCMA field is evolving, continuing to evolve and just preliminary look at the data from ASH certainly does look encouraging for patients' perspective. The and internally, we have data to show that we compare our DAGR So we look forward to sort of sharing more specifics as far as next clinical candidate goes in the coming months, but the data that we do show at SITC is paired with the CD19. So that is a very nice proof of concept for what we can do with the DAGR.

Operator

Our next question is going to come from the line of Tyler Van Buren with TD Cowen. Your line is open. Please go ahead.

Speaker 7

Hey, guys. Thanks very much for the update. Can you talk about the ongoing enrollment of the EXPAND trial? And in particular with the ALLO-five zero one A only arm,

Speaker 2

and if you

Speaker 7

think it will complete enrollment given the lack of 647 being used. I guess my question is, if enrollment ends up being increasingly challenged, which I believe it should, would you aim to go to the FDA by the end Next year with data that you have available around the same time as the Alpha-two readout and could that be sufficient?

Speaker 2

Thanks, Tyler. Again, this is Zach. So as far as the enrollment to the two arms goes, there's no Choice obviously that investigators or patients can make there that's a randomized trial and so that's how that will unfold. And so we don't expect necessarily there will be a disparity in the enrollment if the patients pull out of the The second part of your question around what data And when would we go to the FDA? It's your question is very much centered on how we're thinking about it.

Speaker 2

So as the data from Alpha-two It begins to mature and we have something tangible to take to the FDA. I do think that We would go at the same time with what we have from Xpand. And as a reminder, this study is supported with the Data Safety Monitoring Board who will also Be able to weigh in on the emerging data from that, but that is absolutely a part of our strategy.

Operator

Thank you. And one moment for our next question. And our next question is going to come from the line of Brian Chiang with JPMorgan. Your line is open. Please go ahead.

Speaker 5

Hey guys, thanks for taking my question. On CD70, what will be needed for you to take the program into the pivotal stage? Can you give us a preview on what we deem as the bar to gauge success early next year before dedicating resources to push this program to the next stage? Thank you.

Speaker 2

Thanks, Brian. So what we're looking for, I think in this program is In the neighborhood of what we have shown already as it pertains to the CD70 positive patients, as you recall in the AACR presentation, we had Two groups of patients, one group whose CD70 expression was low or unknown and then one that was measurable and that was a range of And in that CD70 positive group, we saw a response rate of about 30%. So we think that that is Would be a meaningful improvement for what patients currently have on offer and that includes some of the data that's been released More recently, so we can come in around that mark. We do think that is a path towards a pivotal program.

Operator

Thank you. And one moment as we move on to our next question. And our next

Speaker 8

Maybe first on Xpand, I was wondering if you could comment on the geographic build out there. Are you fully satisfied with the footprint in the U. S. In the year? Or do you expect to And then just briefly on the earlier line strategy, you made some comments around Finalizing that and then hopefully providing some updates, do you have any additional comments around timing as it relates to locking in that strategy?

Speaker 2

Thanks, Jack. So as far as Xtand goes, we are still Making progress there. We will intend to bring on Australia in the coming weeks there. So we are still working to expand The footprint there and even within the countries in Europe, we're still adding sites. So we're still in And execution mode for both Alpha-two and Xpand and bringing on new sites to grow that footprint to support enrollment.

Speaker 2

And then the early line study, so

Speaker 8

I will say, again, we're not quite ready to Share

Speaker 2

the details there on what we're thinking, but suffice it to say, we are making good progress internally on The study concept and we are pretty excited about the way that this is taking shape And how it's mirroring the developing practice patterns for diffuse large B cell lymphoma. So We're still on track, I think, to share details around the time that we've guided to. So stay tuned.

Operator

Thank you. And one moment as we move to our next question. And our next question is going to come from the line of Kelsey Goodwin with Guggenheim I guess

Speaker 9

First, regarding the BCMA program, I guess, can you provide any kind of updates there and maybe any learnings from the assessment that you guys have been doing regarding the manufacturing process. And then maybe secondly, Specific to the Notch partnership, I guess, is there any kind of qualitative update you could give or maybe some sort of timing, as you kind of work with them on

Speaker 2

1st one and then you can take and David will take the notch question. So as far as the BCMA program goes, we are still Those programs were not enrolling patients into the BCMA. Currently, we are still sort of Examining the manufacturing process, what I can say, obviously, I won't go into specifics there, but we are Learning as I think every CAR T company is that, there are elements in the manufacturing process that are right for optimization. And I do think that what we are learning across our portfolio on the manufacturing side is that many times what we One program can be translated into another. So we are sort of overall quite excited about the progress that we're making on understanding that manufacturing within the context So Kelsey, on the second question, this is David Chang.

Speaker 2

NASH Therapeutics is Our partner in the ITSC area and we've been working with them now for about 4 years. They have made a tremendous progress in differentiating the iPSC into the CD34 positive stem cells and subsequently after that That's quite a differentiating into the CDAP cells. So the progress is being made and we're working to continue to work very closely with NICE And to incorporate that technology into what we're doing. But given all the things that we are handling now, I think it's going to stay at the research stage for a little bit longer.

Operator

Thank you. And one moment as we move on to our next question. And our next question is going to come from the line of John Newman with Canaccord Genuity, your line is open. Please go ahead.

Speaker 10

Hi there and thank you for taking my question. I just wondered for the ALPHA-two trial, you're allowing, excuse me, outpatient treatment at the investigators discretion. I'm wondering if you expect A substantial number of patients to be treated this way. I also have a question on The enrollment of the clinical sites for the trial, wondering if you've been able to open clinical sites in the EU, Canada and Australia where autologous CD19 CAR Ts are not as widely available or used versus the U. S.

Speaker 10

To help with enrollment? Thanks.

Speaker 2

Thanks, John. So I'll answer the second question first. That has long been part of our strategy for enrollment is to expand into geographies, countries and indeed Reimbursement related or access related, we're sort of encountering all kinds of different reasons why those patients are not getting access to this life saving therapy. So In those cases, having access to a clinical trial such as ALPT-two or Xpand really is welcomed quite hardly by the patients and by The physicians. And sorry, John, I'm blanking on your first question.

Speaker 2

Outpatient. Outpatient, that's right. Thank you, David. So we are seeing actually a fair number of patients being managed fully outpatient and that means both The lymphodepletion as well as the CAR T infusion. And it's been, I would say very encouraging so far and many of the centers that have met with some success in their first few patients continue to have that be Their default position, of course, is a patient needs to come in for 1 or more reasons.

Speaker 2

That's no problem at all. Patients can be admitted. But there seems to be a high level of enthusiasm around managing these patients outpatient. And in fact, some of the centers are actually we're having them talk to other centers

Operator

Our next question is going to come from the line of Kalpip Thill with B. Riley. Your line is open. Please go ahead.

Speaker 11

Good afternoon. This is Andy Pleasure on for Talbot. Thank you for taking the questions. One of your ASH abstracts revealed the impact of recipient's alloreactive CD8 positive T cells and allogeneic CAR T rejection. Can you please elaborate on ways that this could potentially be addressed?

Speaker 2

Sure. Good question. So we've known as I think the field is known and certainly other allogeneic CAR T developers have known that when you take an HLA unmatched product From donor into a patient that the risk of allo rejection is there. And so I think everybody is crafting new strategies around how to mitigate this host versus graft response. What I think Allogene has got that's quite exciting actually As a robust and targeted selective lymphodepletion strategy that the ALLO-six forty seven component And when used paired with our CD52 negative CAR T cells, that is how we have So far, I think rather successfully managed this host versus graft reaction.

Speaker 2

What that abstract is really showing is that this is something that we can Further refined both from an LD strategy, but also we're taking those learnings and folding them into our new product development And looking for ways to through gene engineering or other strategies help to prevent or mitigate that host versus graft and not relying However, I would say that just what we've done so far around lymphodepletion as our clinical data will show We've managed to create a great window of persistence for ourselves where we can see high levels of expansion and persistence And that corresponds to durable complete remission. So I think allogene is on the right track, but the point of that abstract is really There's probably more that we can learn and we're taking that forward into our new product development.

Operator

Thank you. And one moment as we move on to our next question. And our next question is going to come from the line of Sami Corwin with William Blair. Your line is open. Please go ahead.

Speaker 1

Hi. Thanks for taking my question. I noticed in the 10 Q that it was reported that there was some cases of a immune effector cell mitosisocytosis like syndrome. I was wondering if you guys could elaborate on that a little bit and if you think it's related to the DAG or technology at all and if that's what changed the guidance for data on the trial?

Speaker 2

Thanks, Amy, for the question and nice job with that mouthful of a new entity. So The way that we're thinking about IECHS is it's likely probably An umbrella term that has described an inflammatory process that is likely seen across CAR T products. In fact, it's been described in both heme programs, not our heme programs, but others as well as other solid tumor programs. And so

Speaker 4

I I

Speaker 2

think when we see sort of an inflammatory response, we have begun to call that IECHS As opposed to HLH or CRS or ICANN, sometimes this different description is a little bit more straightforward to use. So when it comes to the 3 16 program, we just want to reiterate How careful we want to be as we are moving through this dose escalation. And so this is really the I believe probably some of the best Solid tumor data that has ever been shown for CAR T, especially for an AlloCAR T. And so as we are moving forward, we want to be

Operator

Thank you. And one moment as we move on to our next question. And our next question is going to come from the line of Harteep Singh with Oppenheimer. Your line is open. Please go ahead.

Speaker 4

Great. Thank you. Just got a couple of questions and thanks for all the updates. My question is a little bit more broad. One is just on 501A, your C19 program.

Speaker 4

With the move of, for example, Gilead into second line LBCL, over the last year, are you seeing sort of Changes in those patients that are in 3rd line LBCL, are there more patients? I imagine the patient pool is probably increasing. But where is bone marrow transplant relative to that? Have things changed as those targets therapies have moved up Early in lines of therapy. And then secondly, just on manufacturing follow-up, for your lead program, Are you technically in what would be a commercial material process, meaning that something that you'd be able to file your BLA with?

Speaker 4

Or are you sort of still in

Speaker 2

Yes. Hi, Josh. This is Dave Chang. So let me give Zach a little bit Great. So, it's been answering question after question.

Speaker 2

Your first question about 5018 program and Yes, the approval of avalisartine, the early lines and how that's affecting our study, I think, sort of taking it from that point. Certainly, this is something that we had expected as the CAR T makes a way into the earlier line and We are seeing this both in the CD19 program as well as announced in the today's ASH abstract, a lot of Abstracts cutting in multiple myeloma with the BCMA targeting CARs. So in terms of 501A operative study, The fact still is that there's a large number of patients who are not getting access to the CAR T. So that segment is still open Now for us to tap into Alpha Alpha 2 study. And one of the reasons that we are really Trying to move to the earlier line as quickly as possible is to address this fundamental Changes in the patient flow that we are witnessing in non absence lymphoma and so as to we are certainly I think that made the changes in the multiple myeloma area.

Speaker 2

The second question about the manufacturing, This is something that we have worked on for a while. Just as our CFI manufacturing facility could Potentially support the commercial launch, the process that we are using is really will be the basis for the commercial launch. So the answer to your question is yes.

Operator

Thank you. And one moment as we move on to our next question. And our next question is going to come from the line of Luka Iosai with RBC. Your line is open. Please go ahead.

Speaker 1

Great. Thanks for taking our questions. This is Lisa on for Luca. Can you remind us of the timeline for when ALPHA-two and Xpand could read out? And if you would have sufficient runway that would align with both of those data readouts?

Speaker 1

Thanks.

Speaker 2

Yes. So this is Zach. We are expecting our first Look at the ILK2 data by the end of next year, and we expect to have some of the some at least some out expand data around the same time. So as far as the runway goes, I'll let others speak to it, but at the highest level, yes, we do have runway that would extend beyond those 2 data readouts.

Operator

Thank you. And I would now like to turn the conference back over to David Chang for any closing remarks.

Speaker 2

Thank you for joining us today and your ongoing faith in allogene as we create the code for allogeneic CAR T. We will continue to do everything possible to validate your belief in our ability to make this a reality for patients and look forward to sharing you Sharing with Unisport and Astaxis across our pipeline over the coming months. Operator, you may now disconnect.

Powered by Quartr
Earnings Conference Call
Allogene Therapeutics Q3 2023
00:00 / 00:00